Jessica E Ericson1, Martyn Gostelow, Julie Autmizguine, Christoph P Hornik, Reese H Clark, Daniel K Benjamin, P Brian Smith. 1. From the *Duke Clinical Research Institute, Durham, North Carolina; †Department of Pediatrics, Penn State College of Medicine, Hershey, Pennsylvania; ‡Department of Pediatrics, CHU Sainte Justine, §Department of Pharmacology, University of Montreal, Montreal, Quebec, Canada; ¶Department of Pediatrics, Duke University, Durham, North Carolina; and ‖Pediatrix-Obstetrix Center for Research and Education, Sunrise, Florida.
Abstract
BACKGROUND: Acyclovir is used to treat herpes simplex virus disease in infants. Treatment with high-dose acyclovir, 60 mg/kg/d, is recommended; however, the safety of this dosage has not been assessed in the past 15 years, and this dosage is not currently approved for infants by the US Food and Drug Administration. METHODS: We included infants with neonatal herpes simplex virus disease treated with ≥14 days of intravenous acyclovir starting in the first 120 days of life admitted to 1 of 42 neonatal intensive care units managed by the Pediatrix Medical Group between 2002 and 2012. We determined the frequency and proportion of infants with clinical and laboratory adverse events (AEs) as well as the number and proportion of infant days with laboratory AEs occurring during acyclovir exposure. RESULTS: We identified 89 infants during the study period with 1658 days of acyclovir exposure. Almost all received high-dose acyclovir therapy (79/89, 89%). The most common clinical AEs were hypotension and seizure, both occurring in 9% of infants. Thrombocytopenia was the most common laboratory AE occurring in 25% of infants and on 9% of infant-days. Elevated creatinine occurred in 2% of infants and 0.2% of infant-days and no infants developed renal failure requiring dialysis. Overall, 45% of infants had ≥1 AE. CONCLUSIONS: In this cohort of infants treated during the high-dose acyclovir era, AEs were common but usually not severe. Many of the AEs reported in this cohort may be related to the underlying infection rather than due to acyclovir exposure.
BACKGROUND: Acyclovir is used to treat herpes simplex virus disease in infants. Treatment with high-dose acyclovir, 60 mg/kg/d, is recommended; however, the safety of this dosage has not been assessed in the past 15 years, and this dosage is not currently approved for infants by the US Food and Drug Administration. METHODS: We included infants with neonatal herpes simplex virus disease treated with ≥14 days of intravenous acyclovir starting in the first 120 days of life admitted to 1 of 42 neonatal intensive care units managed by the Pediatrix Medical Group between 2002 and 2012. We determined the frequency and proportion of infants with clinical and laboratory adverse events (AEs) as well as the number and proportion of infant days with laboratory AEs occurring during acyclovir exposure. RESULTS: We identified 89 infants during the study period with 1658 days of acyclovir exposure. Almost all received high-dose acyclovir therapy (79/89, 89%). The most common clinical AEs were hypotension and seizure, both occurring in 9% of infants. Thrombocytopenia was the most common laboratory AE occurring in 25% of infants and on 9% of infant-days. Elevated creatinine occurred in 2% of infants and 0.2% of infant-days and no infants developed renal failure requiring dialysis. Overall, 45% of infants had ≥1 AE. CONCLUSIONS: In this cohort of infants treated during the high-dose acyclovir era, AEs were common but usually not severe. Many of the AEs reported in this cohort may be related to the underlying infection rather than due to acyclovir exposure.
Authors: D W Kimberlin; C Y Lin; R F Jacobs; D A Powell; L M Frenkel; W C Gruber; M Rathore; J S Bradley; P S Diaz; M Kumar; A M Arvin; K Gutierrez; M Shelton; L B Weiner; J W Sleasman; T M de Sierra; S J Soong; J Kiell; F D Lakeman; R J Whitley Journal: Pediatrics Date: 2001-08 Impact factor: 7.124
Authors: Fujie Xu; Maya R Sternberg; Benny J Kottiri; Geraldine M McQuillan; Francis K Lee; Andre J Nahmias; Stuart M Berman; Lauri E Markowitz Journal: JAMA Date: 2006-08-23 Impact factor: 56.272
Authors: Suchitra Rao; Mark J Abzug; Phyllis Carosone-Link; Tori Peterson; Jason Child; Georgette Siparksy; Danielle Soranno; Melissa A Cadnapaphornchai; Eric A F Simões Journal: J Pediatr Date: 2015-02-21 Impact factor: 4.406
Authors: David W Kimberlin; Richard J Whitley; Wen Wan; Dwight A Powell; Gregory Storch; Amina Ahmed; April Palmer; Pablo J Sánchez; Richard F Jacobs; John S Bradley; Joan L Robinson; Mark Shelton; Penelope H Dennehy; Charles Leach; Mobeen Rathore; Nazha Abughali; Peter Wright; Lisa M Frenkel; Rebecca C Brady; Russell Van Dyke; Leonard B Weiner; Judith Guzman-Cottrill; Carol A McCarthy; Jill Griffin; Penelope Jester; Misty Parker; Fred D Lakeman; Huichien Kuo; Choo Hyung Lee; Gretchen A Cloud Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245
Authors: Lena Schleede; Wolfgang Bueter; Sara Baumgartner-Sigl; Thomas Opladen; Katharina Weigt-Usinger; Susanne Stephan; Martin Smitka; Steffen Leiz; Olaf Kaiser; Verena Kraus; Andreas van Baalen; Heino Skopnik; Hans Hartmann; Kevin Rostasy; Thomas Lücke; Ulrike Schara; Martin Häusler Journal: J Child Neurol Date: 2013-01-16 Impact factor: 1.987
Authors: Andrea T Cruz; Stephen B Freedman; Dina M Kulik; Pamela J Okada; Alesia H Fleming; Rakesh D Mistry; Joanna E Thomson; David Schnadower; Joseph L Arms; Prashant Mahajan; Aris C Garro; Christopher M Pruitt; Fran Balamuth; Neil G Uspal; Paul L Aronson; Todd W Lyons; Amy D Thompson; Sarah J Curtis; Paul T Ishimine; Suzanne M Schmidt; Stuart A Bradin; Kendra L Grether-Jones; Aaron S Miller; Jeffrey Louie; Samir S Shah; Lise E Nigrovic Journal: Pediatrics Date: 2018-01-03 Impact factor: 7.124
Authors: Kevin J Downes; Craig L K Boge; Elande Baro; Gerold T Wharton; Kellie M Liston; Brittany L Haltzman; Hannah M Emerson; Edwin Doe; Rosanna Fulchiero; Van Tran; Lilly Yen; Phuong Lieu; Sara L Van Driest; Alison G Grisso; Ida T Aka; Jennifer Hale; Jessica Gillon; Julie S Pingel; Susan E Coffin; Ann W McMahon Journal: J Pediatr Date: 2020-02-06 Impact factor: 4.406
Authors: Christoph P Hornik; Andrew M Atz; Catherine Bendel; Francis Chan; Kevin Downes; Robert Grundmeier; Ben Fogel; Debbie Gipson; Matthew Laughon; Michael Miller; Michael Smith; Chad Livingston; Cindy Kluchar; Anne Heath; Chanda Jarrett; Brian McKerlie; Hetalkumar Patel; Christina Hunter Journal: Appl Clin Inform Date: 2019-05-08 Impact factor: 2.342